139 related articles for article (PubMed ID: 20589893)
1. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.
Nevo Y; Halevy O; Genin O; Moshe I; Turgeman T; Harel M; Biton E; Reif S; Pines M
Muscle Nerve; 2010 Aug; 42(2):218-29. PubMed ID: 20589893
[TBL] [Abstract][Full Text] [Related]
2. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
[TBL] [Abstract][Full Text] [Related]
4. Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate.
Dadush O; Aga-Mizrachi S; Ettinger K; Tabakman R; Elbaz M; Fellig Y; Yanay N; Nevo Y
Neuromuscul Disord; 2010 Apr; 20(4):267-72. PubMed ID: 20304648
[TBL] [Abstract][Full Text] [Related]
5. Halofuginone and muscular dystrophy.
Pines M; Halevy O
Histol Histopathol; 2011 Jan; 26(1):135-46. PubMed ID: 21117034
[TBL] [Abstract][Full Text] [Related]
6. Early pathological signs in young dysf
Barzilai-Tutsch H; Genin O; Pines M; Halevy O
Neuromuscul Disord; 2020 Jun; 30(6):472-482. PubMed ID: 32451154
[TBL] [Abstract][Full Text] [Related]
7. Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.
Wellner G; Mordechay S; Evans P; Genin O; Pines M; Halevy O
Histol Histopathol; 2019 Jul; 34(7):791-801. PubMed ID: 30628720
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.
Roffe S; Hagai Y; Pines M; Halevy O
Exp Cell Res; 2010 Apr; 316(6):1061-9. PubMed ID: 20060825
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.
Mordechay S; Smullen S; Evans P; Genin O; Pines M; Halevy O
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209117
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
11. Halofuginone improves muscle-cell survival in muscular dystrophies.
Bodanovsky A; Guttman N; Barzilai-Tutsch H; Genin O; Levy O; Pines M; Halevy O
Biochim Biophys Acta; 2014 Jul; 1843(7):1339-47. PubMed ID: 24703880
[TBL] [Abstract][Full Text] [Related]
12. Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.
Elbaz M; Yanay N; Aga-Mizrachi S; Brunschwig Z; Kassis I; Ettinger K; Barak V; Nevo Y
Ann Neurol; 2012 May; 71(5):699-708. PubMed ID: 22522482
[TBL] [Abstract][Full Text] [Related]
13. Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy.
Gawlik KI; Li JY; Petersén A; Durbeej M
Hum Mol Genet; 2006 Sep; 15(18):2690-700. PubMed ID: 16893907
[TBL] [Abstract][Full Text] [Related]
14. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.
Huebner KD; Jassal DS; Halevy O; Pines M; Anderson JE
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1550-61. PubMed ID: 18263710
[TBL] [Abstract][Full Text] [Related]
15. Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.
McLoon LK
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1505-7. PubMed ID: 18310507
[No Abstract] [Full Text] [Related]
16. Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice.
Ringelmann B; Röder C; Hallmann R; Maley M; Davies M; Grounds M; Sorokin L
Exp Cell Res; 1999 Jan; 246(1):165-82. PubMed ID: 9882526
[TBL] [Abstract][Full Text] [Related]
17. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies.
Vilquin JT; Kennel PF; Paturneau-Jouas M; Chapdelaine P; Boissel N; Delaère P; Tremblay JP; Scherman D; Fiszman MY; Schwartz K
Gene Ther; 2001 Jul; 8(14):1097-107. PubMed ID: 11526457
[TBL] [Abstract][Full Text] [Related]
18. Halofuginone promotes satellite cell activation and survival in muscular dystrophies.
Barzilai-Tutsch H; Bodanovsky A; Maimon H; Pines M; Halevy O
Biochim Biophys Acta; 2016 Jan; 1862(1):1-11. PubMed ID: 26454207
[TBL] [Abstract][Full Text] [Related]
19. Myoblast transplantations lead to the expression of the laminin alpha 2 chain in normal and dystrophic (dy/dy) mouse muscles.
Vilquin JT; Guérette B; Puymirat J; Yaffe D; Tomé FM; Fardeau M; Fiszman M; Schwartz K; Tremblay JP
Gene Ther; 1999 May; 6(5):792-800. PubMed ID: 10505103
[TBL] [Abstract][Full Text] [Related]
20. A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination.
Patton BL; Wang B; Tarumi YS; Seburn KL; Burgess RW
J Cell Sci; 2008 May; 121(Pt 10):1593-604. PubMed ID: 18430779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
